(Q46125804)

19 December 2017

title

Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options (English)

1 reference

19 December 2017

0 references

1 reference

1

Christopher P Cannon

1 reference

19 December 2017

author name string

Amit Kumar

series ordinal

2

1 reference

19 December 2017

publication date

1 January 2009

1 reference

19 December 2017

published in

Clinical cornerstone

1 reference

19 December 2017

volume

9

1 reference

19 December 2017

issue

4

1 reference

19 December 2017

page(s)

55-68; discussion 69-71

1 reference

19 December 2017

Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: Group I: worldwide demographics of obesity

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

The obesity epidemic, metabolic syndrome and future prevention strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Obesity and diabetes in the developing world--a growing challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Food preferences in human obesity: carbohydrates versus fats

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Sensory and hedonic associations with macronutrient and energy intakes of lean and obese consumers

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Contribution of a sedentary lifestyle and inactivity to the etiology of overweight and obesity: current evidence and research issues

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Presence and progression of abdominal obesity are predictors of future high blood pressure and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Risk factors for arterial hypertension in adults with initial optimal blood pressure: the Strong Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Health risks of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Two-year changes in lipids and lipoproteins associated with the maintenance of a 5% to 10% reduction in initial weight: some findings and some questions

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Bariatric surgery: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Obesity, inflammation, and insulin resistance--a mini-review

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Weight loss reduces C-reactive protein levels in obese postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Physical activity in the treatment of the adulthood overweight and obesity: current evidence and research issues

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Behavioral treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Behavioral treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Behavioral therapy for obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Pharmacologic treatment options for obesity: current and potential medications

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Identification and importance of brown adipose tissue in adult humans

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Orlistat in the long-term treatment of obesity in primary care settings

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Comparison of continuous and intermittent anorectic therapy in obesity.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Meta-analysis: pharmacologic treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Daily high doses of fluoxetine for weight loss and improvement in lifestyle before bariatric surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Antiobesity carbonic anhydrase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Zonisamide for weight loss in obese adults: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Surgical management of morbid obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Surgical treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Trends in bariatric surgical procedures.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Meta-analysis: surgical treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Entero-endocrine changes after gastric bypass in diabetic and nondiabetic patients: a preliminary study.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Short-term changes in insulin resistance following weight loss surgery for morbid obesity: laparoscopic adjustable gastric banding versus laparoscopic Roux-en-Y gastric bypass

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

Improvements in insulin sensitivity and beta-cell function (HOMA) with weight loss in the severely obese. Homeostatic model assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2809%2980005-7

7 January 2021

10.1016/S1098-3597(09)80005-7

Identifiers

DOI

1 reference

19 December 2017

PubMed ID

19789064

1 reference

19 December 2017